Vignola Mark J. 4
4 · Terns Pharmaceuticals, Inc. · Filed Sep 12, 2024
Insider Transaction Report
Form 4
Vignola Mark J.
Chief Financial Officer
Transactions
- Exercise/Conversion
Stock Option (Right to Buy)
2024-09-10−10,000→ 55,000 totalExercise: $5.36Exp: 2032-01-25→ Common Stock (10,000 underlying) - Exercise/Conversion
Common Stock
2024-09-10$5.36/sh+10,000$53,600→ 101,940 total - Sale
Common Stock
2024-09-10$11.00/sh−10,000$110,000→ 91,940 total
Footnotes (2)
- [F1]The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 18, 2024.
- [F2]25% of the shares subject to the option vest on the first anniversary measured from January 1, 2022 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested on the fourth anniversary of the Vesting Commencement Date.